SETD2 and acute myeloid leukemia: Among them, the component C13 effectively decreased H3K36me3 levels and inhibited the SETD2-dependent proliferation of two acute myeloid leukemia cell lines, prioritizing its chemotype as a viable starting point for optimized SETD2 inhibitors.138